• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Genentech

    < Previous 1 2 3 4 5 6 7 Next >
    News headline image
    U.S. FDA Grants Priority Review to Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    Genentech Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    Genentech to Present Data Across Broad and Impactful Neuroscience Portfolio at 2022 AAN Annual Meeting
    From Genentech
    Via Business Wire
    Tickers OTC
    News headline image
    New Data for Genentech’s Evrysdi (risdiplam) Demonstrate Long-Term Efficacy and Safety in a Broad Population of People With Spinal Muscular Atrophy (SMA)
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    New Two-Year Data for Genentech’s Vabysmo and Susvimo Reinforce Potential to Maintain Vision With Fewer Treatments for People With Two Leading Causes of Vision Loss
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    Genentech’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA)
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    The Lancet Publishes Studies Showing Genentech’s Faricimab Improved and Maintained Vision in Two Leading Causes of Vision Loss, Extending Time Between Treatments up to Four Months
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    Genentech’s Polivy Combination Reduced the Risk of Disease Worsening or Death by 27% in People With Previously Untreated Aggressive Form of Lymphoma
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    Interim Data From Phase III HAVEN 6 Study Demonstrate Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    Genentech Presents Pivotal Data at ASH 2021 for Novel Cancer Immunotherapy Mosunetuzumab
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    New Data From the Phase II CITYSCAPE Trial Show Encouraging Results With Genentech’s Novel Anti-TIGIT Tiragolumab Plus Tecentriq
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    Genentech to Present New Pivotal Data at ASH 2021 From Broad and Comprehensive Portfolio, Challenging Treatment Standards for People With Blood Disorders
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    FDA Approves Genentech’s Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD)
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    FDA Approves Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    New 4-Year Data Show Genentech’s Enspryng (satralizumab-mwge) Significantly Reduces Debilitating Relapses in People With Neuromyelitis Optica Spectrum Disorder
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    New Data up to 8-Years for Genentech’s Ocrevus (ocrelizumab) Show Early and Ongoing Treatment Significantly Reduced Risk of Requiring a Walking Aid in Relapsing Multiple Sclerosis and Disability Progression in Primary Progressive Multiple Sclerosis
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    Genentech’s Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer’s Disease
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    Ad hoc announcement pursuant to Art. 53 LR: Genentech’s Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer’s Disease
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    Genentech to Present New Data on Ocrevus (ocrelizumab) in Multiple Sclerosis and Enspryng (satralizumab-mwge) in Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2021
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    New Phase III Data Support the Benefit of Genentech’s Tecentriq in Early-stage Lung Cancer
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    Genentech to Present Data From Industry-Leading Portfolio at ESMO 2021 Showing Significant Progress in Early Stage and Uncommon Cancers
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    Genentech Provides Update on Tecentriq U.S. Indication for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    Phase III Study Shows Genentech's Polivy Plus R-CHP Is the First Regimen in 20 Years to Significantly Improve Outcomes in Previously Untreated Aggressive Form of Lymphoma Compared to Standard of Care
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    FDA Grants Priority Review to Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-small Cell Lung Cancer
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    Data for Genentech’s Evrysdi (risdiplam) Published in New England Journal of Medicine Shows Significant Improvement in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    FDA Grants Breakthrough Therapy Designation for Venclexta in Combination With Azacitidine for the Treatment of Patients With Myelodysplastic Syndromes
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    New Data for Genentech’s Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A
    From Genentech
    Via Business Wire
    Tickers RHHBY
    News headline image
    Genentech’s Actemra Receives FDA Emergency Use Authorization for the Treatment of COVID-19 In Hospitalized Adults and Children
    From Genentech
    Via Business Wire
    Tickers RHHBY
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.